AKP07

AKP07 is a nutraceutical candidate currently in development by Akademy Pharma, a subsidiary of the Italian pharmaceutical company Damor Farmaceutici. Positioned within the emerging field of cardio-oncology, AKP07 is intended to manage or mitigate cardiovascular complications associated with cancer or its treatment. As a nutraceutical, it is likely derived from natural sources, consistent with Damor Farmaceutici's focus on biopharmaceuticals like *Triticum vulgare* extract, although the specific composition and molecular targets of AKP07 remain proprietary and have not been disclosed in public pipeline documentation.